The COVID-19 pandemic has brought new attention to an old problem: multidrug resistant bacteria.

The increased utilization of antibiotics in the treatment of COVID-19 as well as the widespread usage of antibiotics in industrial livestock farming are driving the resistance of bacteria against existing antiobiotic treatments. 

Novel antibiotics

To treat multidrug resistant bacteria, scientics are exploring new mechanisms of action.

KnowledgeAgent’s pharma team offers its customers an overview of new mechanisms of action and the development stages of novel antibiotics which utilize these new mechanisms.

The team has identified critical bacterial strains and is able to map which novel antibiotics target which strains.

Especially high demand exists for Clostridium difficile. KnowledgeAgent’s pharma team shows which novel antibiotics are being developed for this strain and which mechanisms of action are being pursued in development.

The team has summarized its results in a research brief which can be downloaded here.

Do you have questions regarding the brief or would like to get to know our pharma team? Contact us!